{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"97","value":"83"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"51","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Probability of Event-free Survival (EFS) for Patients after 18 months. An event is either treatment related mortality (TRM), primary or secondary graft failure, or relapse/non-response (as defined in protocol section 10). Time to event is time from transplant with patients who die between the start of the conditioning regimen and transplant given a time to event of zero.","dispersionType":"95% Confidence Interval","groups":[{"description":"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.\n\nTRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.\n\nPatients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor).\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic HCT\n\nBusulfan: Given IV\n\nCyclophosphamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nPharmacological Study: Correlative studies\n\nTacrolimus: Given IV or PO","id":"OG000","title":"Arm I (Busulfan, Cyclophosphamide, Melphalan)"},{"description":"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.\n\nTRANSPLANT: Patients undergo allogeneic HCT as in Arm I.\n\nPatients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor).\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic HCT\n\nBusulfan: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPharmacological Study: Correlative studies\n\nTacrolimus: Given IV or PO","id":"OG001","title":"Arm II (Busulfan, Fludarabine Phosphate)"}],"paramType":"NUMBER","populationDescription":"All eligible randomized patients","reportingStatus":"POSTED","timeFrame":"From transplant up to 18 months","title":"Percent Probability of Event-free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"percent probability"}